{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:47:55Z","timestamp":1790736475484,"version":"4.1.0"},"reference-count":213,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82020108018"],"award-info":[{"award-number":["82020108018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32595501"],"award-info":[{"award-number":["32595501"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32225029"],"award-info":[{"award-number":["32225029"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014219","name":"National Science Fund for Distinguished Young Scholars","doi-asserted-by":"publisher","award":["82325026"],"award-info":[{"award-number":["82325026"]}],"id":[{"id":"10.13039\/501100014219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2605003"],"award-info":[{"award-number":["2023YFC2605003"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["039GJHZ2025085GC"],"award-info":[{"award-number":["039GJHZ2025085GC"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jconrel.2026.114729","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T15:51:52Z","timestamp":1771084312000},"page":"114729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Nucleic acid drug delivery in ophthalmology: Emerging trends and future perspectives"],"prefix":"10.1016","volume":"392","author":[{"given":"Hengye","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songzhang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.114729_bb0005","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41392-024-02035-4","article-title":"Nucleic acid drugs: recent progress and future perspectives","volume":"9","author":"Sun","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.114729_bb0010","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41578-022-00529-7","article-title":"Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs","volume":"8","author":"Dilliard","year":"2023","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2026.114729_bb0015","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41577-024-01064-y","article-title":"Redefining our vision: an updated guide to the ocular immune system","volume":"24","author":"Wu","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.114729_bb0020","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/gt.2011.161","article-title":"Gene supplementation therapy for recessive forms of inherited retinal dystrophies","volume":"19","author":"Smith","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2026.114729_bb0025","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41433-020-0770-y","article-title":"Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases","volume":"34","author":"Seah","year":"2020","journal-title":"Eye"},{"key":"10.1016\/j.jconrel.2026.114729_bb0030","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/s41385-022-00551-6","article-title":"Mucosal immunology of the ocular surface","volume":"15","author":"de Paiva","year":"2022","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.jconrel.2026.114729_bb0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41536-025-00396-0","article-title":"Advancements in bioengineering for descemet membrane endothelial keratoplasty (DMEK)","volume":"10","author":"Zwingelberg","year":"2025","journal-title":"npj Regener. Med."},{"key":"10.1016\/j.jconrel.2026.114729_bb0040","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41433-020-0809-0","article-title":"Advances in ocular drug delivery systems","volume":"34","author":"Kang-Mieler","year":"2020","journal-title":"Eye"},{"key":"10.1016\/j.jconrel.2026.114729_bb0045","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nri.2017.100","article-title":"Organ-specific protection mediated by cooperation between vascular and epithelial barriers","volume":"17","author":"Spadoni","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.114729_bb0050","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/gels8020082","article-title":"Drug delivery challenges and current progress in nanocarrier-based ocular therapeutic system","volume":"8","author":"Akhter","year":"2022","journal-title":"Gels"},{"key":"10.1016\/j.jconrel.2026.114729_bb0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.addr.2017.04.001","article-title":"Nanoparticles for drug delivery to the anterior segment of the eye","volume":"122","author":"Janagam","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114729_bb0060","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202470194","article-title":"Innovative nanotechnology in drug delivery systems for advanced treatment of posterior segment ocular diseases","volume":"11","author":"Wu","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2026.114729_bb0065","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jtos.2017.03.006","article-title":"TFOS DEWS II tear film report","volume":"15","author":"Willcox","year":"2017","journal-title":"Ocular Surface"},{"key":"10.1016\/j.jconrel.2026.114729_bb0070","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1016\/j.bbamem.2016.02.020","article-title":"Tear film lipid layer: a molecular level view","volume":"1858","author":"Cwiklik","year":"2016","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.jconrel.2026.114729_bb0075","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/bjo.82.4.453","article-title":"Tear lipocalin and the eye\u2019s front line of defence","volume":"82","author":"Gachon","year":"1998","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2026.114729_bb0080","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.3389\/fphar.2019.01560","article-title":"Albumin levels in tear film modulate the bioavailability of medically-relevant topical drugs","volume":"10","author":"Sebbag","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.114729_bb0085","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ijpharm.2017.09.018","article-title":"Physicochemical properties of mucus and their impact on transmucosal drug delivery","volume":"532","author":"Leal","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.114729_bb0090","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0939-6411(97)00064-7","article-title":"Ocular pharmacokinetics\/pharmacodynamics","volume":"44","author":"Worakul","year":"1997","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.114729_bb0095","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3109\/02713688509025145","article-title":"Transport processes across the rabbit corneal epithelium - a review","volume":"4","author":"Klyce","year":"1985","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.jconrel.2026.114729_bb0100","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jconrel.2021.04.008","article-title":"Challenges and strategies for the delivery of biologics to the cornea","volume":"333","author":"Wels","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114729_bb0105","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1021\/js9802594","article-title":"Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye","volume":"87","author":"Prausnitz","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.114729_bb0110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jsb.2009.03.012","article-title":"Determining the mechanical properties of human corneal basement membranes with atomic force microscopy","volume":"167","author":"Last","year":"2009","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.jconrel.2026.114729_bb0115","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ejpb.2015.02.032","article-title":"Undefined role of mucus as a barrier in ocular drug delivery","volume":"96","author":"Ruponen","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.114729_bb0120","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejps.2018.03.034","article-title":"Corneal and conjunctival drug permeability: systematic comparison and pharmacokinetic impact in the eye","volume":"119","author":"Ramsay","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.114729_bb0125","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF02569055","article-title":"The blood-ocular barriers: past, present, and future","volume":"93","author":"Cunha-Vaz","year":"1997","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.jconrel.2026.114729_bb0130","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1517\/17425247.5.5.567","article-title":"Ocular novel drug delivery: impacts of membranes and barriers","volume":"5","author":"Barar","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.114729_bb0135","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1517\/17425247.4.4.371","article-title":"Novel approaches to retinal drug delivery","volume":"4","author":"Janoria","year":"2007","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.114729_bb0140","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular drug delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2026.114729_bb0145","doi-asserted-by":"crossref","first-page":"7947","DOI":"10.2147\/IJN.S150366","article-title":"Tailored nanostructured platforms for boosting transcorneal permeation: box-Behnken statistical optimization, comprehensive in vitro, ex vivo and in vivo characterization","volume":"12","author":"Elsayed","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.114729_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2020.102342","article-title":"Strategies to prolong the residence time of drug delivery systems on ocular surface","volume":"288","author":"Grassiri","year":"2021","journal-title":"Adv. Colloid Interf. Sci."},{"key":"10.1016\/j.jconrel.2026.114729_bb0155","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jtos.2023.09.008","article-title":"Intrastromal versus subconjunctival injection of mesenchymal stem\/stromal cells for promoting corneal repair","volume":"30","author":"Soleimani","year":"2023","journal-title":"Ocular Surface"},{"key":"10.1016\/j.jconrel.2026.114729_bb0160","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/IJG.0000000000001451","article-title":"Evolving guidelines for Intracameral injection","volume":"29","author":"Liebmann","year":"2020","journal-title":"J. Glaucoma"},{"key":"10.1016\/j.jconrel.2026.114729_bb0165","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.jcrs.2014.10.010","article-title":"Intracameral antibiotics: safety, efficacy, and preparation","volume":"40","author":"Braga-Mele","year":"2014","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jconrel.2026.114729_bb0170","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/ICU.0b013e32835a93be","article-title":"Role of topical, subconjunctival, intracameral, and irrigative antibiotics in cataract surgery","volume":"24","author":"Vazirani","year":"2013","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.jconrel.2026.114729_bb0175","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jconrel.2023.07.055","article-title":"Challenges and strategies for ocular posterior diseases therapy via non-invasive advanced drug delivery","volume":"361","author":"Qi","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114729_bb0180","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1517\/17425247.2014.927864","article-title":"Intravitreal drug delivery in retinal disease: are we out of our depth?","volume":"11","author":"Thakur","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.114729_bb0185","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11095-008-9745-6","article-title":"Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina","volume":"26","author":"Kim","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.114729_bb0190","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jconrel.2013.01.018","article-title":"Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo","volume":"167","author":"Xu","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114729_bb0195","series-title":"Webvision: The Organization of the Retina and Visual System [Internet]","author":"Kolb","year":"1995"},{"key":"10.1016\/j.jconrel.2026.114729_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114770","article-title":"Polymer- and lipid-based nanocarriers for ocular drug delivery: current status and future perspectives","volume":"196","author":"Han","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114729_bb0205","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/pharmaceutics14010090","article-title":"Lipid nanoparticles for the posterior eye segment","volume":"14","author":"Bonilla","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114729_bb0210","first-page":"443","article-title":"Protein delivery for retinal diseases: from basic considerations to clinical applications","volume":"29","author":"El Sanharawi","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.114729_bb0215","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0014-4835(03)00213-6","article-title":"The blood-retinal barriers system. Basic concepts and clinical evaluation","volume":"78","author":"Cunha-Vaz","year":"2004","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2026.114729_bb0220","series-title":"Ocular Transporters and Receptors: Their Role in Drug Delivery","author":"Mitra","year":"2013"},{"key":"10.1016\/j.jconrel.2026.114729_bb0225","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1167\/iovs.04-1051","article-title":"Permeability of retinal pigment epithelium:: effects of permeant molecular weight and lipophilicity","volume":"46","author":"Pitk\u00e4nen","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2026.114729_bb0230","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12951-023-01992-2","article-title":"Nanotechnology-based ocular drug delivery systems: recent advances and future prospects","volume":"21","author":"Li","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2026.114729_bb0235","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/aos.14042","article-title":"Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach","volume":"97","author":"Habot-Wilner","year":"2019","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.jconrel.2026.114729_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102440","article-title":"Nucleic acid therapeutics: past, present, and future","volume":"36","author":"Naeem","year":"2025","journal-title":"Mol. Ther. Nucl. Acids"},{"key":"10.1016\/j.jconrel.2026.114729_bb0245","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.tibtech.2024.05.002","article-title":"Ocular RNA nanomedicine: engineered delivery nanoplatforms in treating eye diseases","volume":"42","author":"Zhang","year":"2024","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.jconrel.2026.114729_bb0250","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.114729_bb0255","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.114729_bb0260","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.addr.2009.04.004","article-title":"siRNA vs. shRNA: similarities and differences","volume":"61","author":"Rao","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114729_bb0265","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","article-title":"Origins and mechanisms of miRNAs and siRNAs","volume":"136","author":"Carthew","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.114729_bb0270","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.114729_bb0275","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at High cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.114729_bb0280","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.114729_bb0285","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1126\/science.287.5454.820","article-title":"Biochemistry - adaptive recognition by nucleic acid aptamers","volume":"287","author":"Hermann","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.114729_bb0290","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1146\/annurev.med.56.062904.144915","article-title":"Aptamers: an emerging class of therapeutics","volume":"56","author":"Nimjee","year":"2005","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jconrel.2026.114729_bb0295","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.114729_bb0300","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.114729_bb0305","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.114729_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.53388\/BMEC2024001","article-title":"mRNA vaccine: a new generation of technology revolution in biomedicine","volume":"3","author":"Zhong","year":"2024","journal-title":"Biomed. Eng. Commun."},{"key":"10.1016\/j.jconrel.2026.114729_bb0315","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41541-025-01302-x","article-title":"Establishing long-lasting vaccine immunity: insights from mRNA and adjuvanted protein platforms","volume":"10","author":"Pineda-Pe\u00f1a","year":"2025","journal-title":"npj Vaccines"},{"key":"10.1016\/j.jconrel.2026.114729_bb0320","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41576-019-0158-7","article-title":"The biogenesis, biology and characterization of circular RNAs","volume":"20","author":"Kristensen","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jconrel.2026.114729_bb0325","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1038\/s41467-018-05096-6","article-title":"Engineering circular RNA for potent and stable translation in eukaryotic cells","volume":"9","author":"Wesselhoeft","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114729_bb0330","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.addr.2009.02.008","article-title":"Tissue-specific and transcription factor-mediated nuclear entry of DNA","volume":"61","author":"Miller","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114729_bb0335","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041312","article-title":"Trial by \u201cfirsts\u201d: clinical trial design and regulatory considerations in the development and approval of the first AAV gene therapy product in the United States","volume":"13","author":"Reape","year":"2023","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.jconrel.2026.114729_bb0340","doi-asserted-by":"crossref","first-page":"7","DOI":"10.53388\/BMEC2023008","article-title":"CRISPR system contributes to deciphering the pharmaceutical compounds from TCM","volume":"2","author":"Wu","year":"2023","journal-title":"Biomed. Eng. Commun."},{"key":"10.1016\/j.jconrel.2026.114729_bb0345","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nbt.2842","article-title":"CRISPR-Cas systems for editing, regulating and targeting genomes","volume":"32","author":"Sander","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.114729_bb0350","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2017.09.012","article-title":"Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications","volume":"266","author":"Liu","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114729_bb0355","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.114729_bb0360","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"Biodrugs"},{"key":"10.1016\/j.jconrel.2026.114729_bb0365","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/gt.2011.151","article-title":"Novel adeno-associated viral vectors for retinal gene therapy","volume":"19","author":"Vandenberghe","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2026.114729_bb0370","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mt.2009.255","article-title":"Effect of genome size on AAV vector packaging","volume":"18","author":"Wu","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.114729_bb0375","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1038\/s41591-025-03750-3","article-title":"AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trial","volume":"31","author":"Butterfield","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.114729_bb0380","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1126\/science.aah6192","article-title":"Lentiviral vectors, two decades later","volume":"353","author":"Naldini","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.114729_bb0385","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s12033-007-0010-8","article-title":"Gene delivery by lentivirus vectors","volume":"36","author":"Cockrell","year":"2007","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.114729_bb0390","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2026.114729_bb0395","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1099\/0022-1317-81-11-2573","article-title":"Update an adenovirus and its vectors","volume":"81","author":"Russell","year":"2000","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.jconrel.2026.114729_bb0400","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.trecan.2024.11.011","article-title":"Turning cold into hot: emerging strategies to fire up the tumor microenvironment","volume":"11","author":"Ma","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jconrel.2026.114729_bb0405","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41434-020-00205-x","article-title":"Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1","volume":"28","author":"Kim","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2026.114729_bb0410","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nbt.1769","article-title":"Gene therapy finds its niche","volume":"29","author":"Sheridan","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.114729_bb0415","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1126\/science.358.6363.582","article-title":"A second chance","volume":"358","author":"Kaiser","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.114729_bb0420","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1089\/nat.2018.0726","article-title":"Current status of messenger RNA delivery systems","volume":"28","author":"Stanton","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.jconrel.2026.114729_bb0425","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13073-017-0450-0","article-title":"Advances in the delivery of RNA therapeutics: from concept to clinical reality","volume":"9","author":"Kaczmarek","year":"2017","journal-title":"Genome Med."},{"key":"10.1016\/j.jconrel.2026.114729_bb0430","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.addr.2020.06.007","article-title":"Engineering the drug carrier biointerface to overcome biological barriers to drug delivery","volume":"167","author":"Finbloom","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114729_bb0435","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1021\/acsnano.4c09566","article-title":"Transforming medicine: cutting-edge applications of nanoscale materials in drug delivery","volume":"19","author":"Tenchov","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114729_bb0440","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/21548331.1992.11705537","article-title":"Liposomes: realizing their promise","volume":"27","author":"Bangham","year":"1992","journal-title":"Hosp. Pract."},{"key":"10.1016\/j.jconrel.2026.114729_bb0445","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0014-5793(87)80506-9","article-title":"Large unilamellar liposomes with low uptake into the reticuloendothelial system","volume":"223","author":"Allen","year":"1987","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jconrel.2026.114729_bb0450","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejps.2013.02.011","article-title":"DNA delivery via cationic solid lipid nanoparticles (SLNs)","volume":"49","author":"Carrillo","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.114729_bb0455","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1038\/s41467-021-27493-0","article-title":"An ionizable lipid toolbox for RNA delivery","volume":"12","author":"Han","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114729_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115446","article-title":"Breaking the final barrier: evolution of cationic and ionizable lipid structure in lipid nanoparticles to escape the endosome","volume":"214","author":"Mrksich","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114729_bb0465","doi-asserted-by":"crossref","first-page":"6527","DOI":"10.1039\/D3TB00649B","article-title":"Rational design and combinatorial chemistry of ionizable lipids for RNA delivery","volume":"11","author":"Xu","year":"2023","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2026.114729_bb0470","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109256118","article-title":"On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles","volume":"118","author":"Dilliard","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.114729_bb0475","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.addr.2020.06.014","article-title":"Polymeric vehicles for nucleic acid delivery","volume":"156","author":"Piotrowski-Daspit","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114729_bb0480","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.canlet.2019.04.040","article-title":"Nanoparticles for nucleic acid delivery: applications in cancer immunotherapy","volume":"458","author":"Mukalel","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2026.114729_bb0485","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2174\/1566523043345940","article-title":"Towards multifunctional synthetic vectors","volume":"4","author":"Demeneix","year":"2004","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.jconrel.2026.114729_bb0490","series-title":"Nonviral Vectors for Gene Therapy Lipid- and Poiymer-Based Gene Transfer","first-page":"263","article-title":"Recent developments in nucleic acid delivery with polyethylenimines","author":"Neuberg","year":"2014"},{"key":"10.1016\/j.jconrel.2026.114729_bb0495","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jconrel.2019.08.024","article-title":"Poly(\u03b2-amino ester)-based gene delivery systems: from discovery to therapeutic applications","volume":"310","author":"Cordeiro","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114729_bb0500","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.omtn.2023.04.019","article-title":"Poly(\u03b2-amino ester)s-based nanovehicles: structural regulation and gene delivery","volume":"32","author":"Zhang","year":"2023","journal-title":"Mol. Ther. Nucl. Acids"},{"key":"10.1016\/j.jconrel.2026.114729_bb0505","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1038\/s41467-025-59490-y","article-title":"Rational development of gemcitabine-based nanoplatform for targeting SERPINB9\/Granzyme B axis to overcome chemo-immune-resistance","volume":"16","author":"Huang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114729_bb0510","doi-asserted-by":"crossref","first-page":"6617","DOI":"10.3390\/ijms21186617","article-title":"Quaternary ammonium Chitosans: the importance of the positive fixed charge of the drug delivery systems","volume":"21","author":"Fabiano","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.114729_bb0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.53388\/BMEC2023002","article-title":"Recent advances in endogenous and exogenous stimuli-responsive nanoplatforms for bacterial infection treatment","volume":"2","author":"Wu","year":"2023","journal-title":"Biomed. Eng. Commun."},{"key":"10.1016\/j.jconrel.2026.114729_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123680","article-title":"Polymer-based gene-drug co-delivery system effectively inhibits pathologic retinal neovascularization through dual anti-inflammatory and anti-neovascular actions","volume":"326","author":"He","year":"2026","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.114729_bb0525","doi-asserted-by":"crossref","first-page":"37383","DOI":"10.1021\/acsami.5c07366","article-title":"The Nanocarrier landscape-evaluating key drug delivery vehicles and their capabilities: a translational perspective","volume":"17","author":"Khalid-Salako","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2026.114729_bb0530","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1021\/acsmaterialslett.5c01046","article-title":"Multifunctional gold nanoparticles in spinal cord injury Theranostics: from real-time imaging to microenvironment modulation","volume":"7","author":"Zhou","year":"2025","journal-title":"ACS Mater. Lett."},{"key":"10.1016\/j.jconrel.2026.114729_bb0535","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.2147\/IJN.S140772","article-title":"Gold nanoparticles enlighten the future of cancer theranostics","volume":"12","author":"Guo","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.114729_bb0540","doi-asserted-by":"crossref","first-page":"16800","DOI":"10.1021\/am504139d","article-title":"Synergetic approach for simple and rapid conjugation of gold nanoparticles with oligonucleotides","volume":"6","author":"Li","year":"2014","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2026.114729_bb0545","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.addr.2019.01.005","article-title":"Iron oxide nanoparticles: diagnostic, therapeutic and theranostic applications","volume":"138","author":"Dadfar","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114729_bb0550","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/polym8110392","article-title":"Preparation of magnetic Iron oxide nanoparticles (MIONs) with improved saturation magnetization using multifunctional polymer ligand","volume":"8","author":"Majeed","year":"2016","journal-title":"Polymers"},{"key":"10.1016\/j.jconrel.2026.114729_bb0555","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jconrel.2020.07.004","article-title":"Topical siRNA delivery to the cornea and anterior eye by hybrid silicon-lipid nanoparticles","volume":"326","author":"Baran-Rachwalska","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114729_bb0560","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.70010","article-title":"Nano approaches to nucleic acid delivery: barriers, solutions, and current landscape","volume":"17","author":"Gonzalez","year":"2025","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2026.114729_bb0565","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.addr.2016.02.006","article-title":"Extracellular vesicles for drug delivery","volume":"106","author":"Vader","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114729_bb0570","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.addr.2021.03.005","article-title":"Nucleic acid delivery with extracellular vesicles","volume":"173","author":"Michaela","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114729_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114068","article-title":"Molecular engineering of extracellular vesicles for drug delivery: strategies, challenges, and perspectives","volume":"386","author":"Dave","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114729_bb0580","doi-asserted-by":"crossref","first-page":"9448","DOI":"10.1038\/s41467-025-64486-9","article-title":"Super mitochondria-enriched extracellular vesicles enable enhanced mitochondria transfer","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114729_bb0585","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/ijc.35055","article-title":"Enhancing precision targeting of ovarian cancer tumor cells in vivo through extracellular vesicle engineering","volume":"155","author":"Alharbi","year":"2024","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2026.114729_bb0590","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.ymthe.2018.05.024","article-title":"Optimized cholesterol-siRNA chemistry improves productive loading onto extracellular vesicles","volume":"26","author":"Haraszti","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.114729_bb0595","doi-asserted-by":"crossref","first-page":"7","DOI":"10.53388\/BMEC2023011","article-title":"The mesenchymal stem cell regulates the immune system: secretion of cytokines, cell-to-cell contact and extracellular vesicles","volume":"2","author":"Lai","year":"2023","journal-title":"Biomed. Eng. Commun."},{"key":"10.1016\/j.jconrel.2026.114729_bb0600","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1038\/ncomms3980","article-title":"Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs","volume":"4","author":"Villarroya-Beltri","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114729_bb0605","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202403935","article-title":"Membrane fusion-mediated loading of therapeutic siRNA into exosome for tissue-specific application","volume":"36","author":"Xie","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.114729_bb0610","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2023.2288797","article-title":"Multifunctional cell membranes-based nano-carriers for targeted therapies: a review of recent trends and future perspective","volume":"30","author":"Li","year":"2023","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.114729_bb0615","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jconrel.2018.08.033","article-title":"Bioinspired and biomimetic systems for advanced drug and gene delivery","volume":"287","author":"Sabu","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114729_bb0620","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1021\/acsabm.4c00074","article-title":"T cell and natural killer cell membrane-camouflaged nanoparticles for cancer and viral therapies","volume":"7","author":"Ozsoy","year":"2024","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.jconrel.2026.114729_bb0625","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/17425247.2021.1922387","article-title":"Unleashing the potential of cell membrane-based nanoparticles for COVID-19 treatment and vaccination","volume":"18","author":"Pereira-Silva","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.114729_bb0630","first-page":"33","article-title":"Membrane-coated nanoparticles as a biomimetic targeted delivery system for tumour therapy","volume":"5","author":"Guo","year":"2024","journal-title":"Biomater. Transl."},{"key":"10.1016\/j.jconrel.2026.114729_bb0635","article-title":"Research progress of cell membrane biomimetic nanoparticles for circulating tumor cells","volume":"14","author":"Zhang","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2026.114729_bb0640","doi-asserted-by":"crossref","first-page":"17080","DOI":"10.1021\/acsnano.1c03800","article-title":"Cell membrane-coated mimics: a methodological approach for fabrication, characterization for therapeutic applications, and challenges for clinical translation","volume":"15","author":"Chugh","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114729_bb0645","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.3390\/pharmaceutics15071899","article-title":"Recent advances in cell membrane coated-nanoparticles as drug delivery Systems for Tackling Urological Diseases","volume":"15","author":"Yao","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114729_bb0650","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.7150\/thno.48407","article-title":"An electroporation strategy to synthesize the membrane-coated nanoparticles for enhanced anti-inflammation therapy in bone infection","volume":"11","author":"Shi","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2026.114729_bb0655","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3390\/life10120366","article-title":"Virus-like particle mediated CRISPR\/Cas9 delivery for efficient and safe genome editing","volume":"10","author":"Lyu","year":"2020","journal-title":"Life-Basel"},{"key":"10.1016\/j.jconrel.2026.114729_bb0660","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2026.114729_bb0665","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in vivo delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.114729_bb0670","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1021\/acs.molpharmaceut.4c00994","article-title":"Insights from computational studies of polymeric systems for nucleic acid delivery","volume":"22","author":"Ziebarth","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.114729_bb0675","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jconrel.2023.08.058","article-title":"Engineered peptide-drug conjugate provides sustained protection of retinal ganglion cells with topical administration in rats","volume":"362","author":"Hsueh","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114729_bb0680","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11095-022-03385-w","article-title":"Directing the way-receptor and chemical targeting strategies for nucleic acid delivery","volume":"40","author":"Steffens","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.114729_bb0685","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","article-title":"Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates","volume":"40","author":"Brown","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.114729_bb0690","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.ymthe.2018.09.004","article-title":"Development of targeted siRNA Nanocomplexes to prevent fibrosis in experimental Glaucoma filtration surgery","volume":"26","author":"Fernando","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.114729_bb0695","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.ymthe.2023.05.002","article-title":"Enhanced adipose-derived stem cells with IGF-1-modified mRNA promote wound healing following corneal injury","volume":"31","author":"Yu","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.114729_bb0700","article-title":"Genome editing VEGFA prevents corneal neovascularization in vivo","volume":"11","author":"Zeng","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2026.114729_bb0705","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jconrel.2022.08.042","article-title":"LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea","volume":"350","author":"Mohanna","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114729_bb0710","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201803239","article-title":"Intracameral delivery of layer-by-layer coated siRNA nanoparticles for Glaucoma therapy","volume":"14","author":"Dillinger","year":"2018","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2026.114729_bb0715","doi-asserted-by":"crossref","first-page":"11199","DOI":"10.1073\/pnas.1706193114","article-title":"CRISPR-Cas9-based treatment of myocilin-associated glaucoma","volume":"114","author":"Jain","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.114729_bb0720","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.apsb.2020.03.002","article-title":"Inhibition of post-trabeculectomy fibrosis via topically instilled antisense oligonucleotide complexes co-loaded with fluorouracil","volume":"10","author":"Jiang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2026.114729_bb0725","article-title":"Cornea-SELEX for aptamers targeting the surface of eyes and liposomal drug delivery","volume":"4","author":"Wong","year":"2024","journal-title":"Exploration"},{"key":"10.1016\/j.jconrel.2026.114729_bb0730","article-title":"Tetrahedral DNA-based functional MicroRNA-21 delivery system: application to corneal epithelial wound healing","volume":"13","author":"Li","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2026.114729_bb0735","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jconrel.2010.06.006","article-title":"Polymeric micelle gene delivery of bcl-xL via eye drop reduced corneal apoptosis following epithelial debridement","volume":"147","author":"Tong","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114729_bb0740","article-title":"LNP-encapsulated miRNA29b for corneal repair: a novel approach to combat fibrosis","volume":"32","author":"Li","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.jconrel.2026.114729_bb0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113681","article-title":"TGFBI R124H mutant allele silencing in granular corneal dystrophy type 2 using topical siRNA delivery","volume":"382","author":"McLain","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114729_bb0750","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/mt.2013.216","article-title":"In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of Glaucoma","volume":"22","author":"Mart\u00ednez","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.114729_bb0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123353","article-title":"MicroRNA-loaded antioxidant nanoplatforms for prevention and treatment of experimental acute and chronic uveitis","volume":"322","author":"Sheng","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.114729_bb0760","first-page":"640","article-title":"MiRNA 24-3p-rich exosomes functionalized DEGMA-modified hyaluronic acid hydrogels for corneal epithelial healing","volume":"25","author":"Sun","year":"2023","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.jconrel.2026.114729_bb0765","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ymthe.2019.12.012","article-title":"Gene therapy for Glaucoma by ciliary body aquaporin 1 disruption using CRISPR-Cas9","volume":"28","author":"Wu","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.114729_bb0770","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.1038\/s41467-024-50050-4","article-title":"CRISPR-CasRx-mediated disruption of Aqp1\/Adrb2\/Rock1\/Rock2 genes reduces intraocular pressure and retinal ganglion cell damage in mice","volume":"15","author":"Yao","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114729_bb0775","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/iovs.64.10.2","article-title":"DPP-4 inhibitors attenuate fibrosis after Glaucoma filtering surgery by suppressing the TGF-\u03b2\/Smad signaling pathway","volume":"64","author":"Yoshida","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2026.114729_bb0780","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12951-018-0425-3","article-title":"In vitro and in vivo delivery of a sustained release nanocarrier-based formulation of an MRTF\/SRF inhibitor in conjunctival fibrosis","volume":"16","author":"Tagalakis","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2026.114729_bb0785","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41392-024-02119-1","article-title":"Identification of glutamine as a potential therapeutic target in dry eye disease","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.114729_bb0790","doi-asserted-by":"crossref","first-page":"2415341","DOI":"10.1002\/advs.202415341","article-title":"M6A modified miR-31-5p suppresses M1 macrophage polarization and autoimmune dry eye by targeting P2RX7","volume":"12","author":"Zhao","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2026.114729_bb0795","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1252557","article-title":"Umbilical cord mesenchymal stem cell-derived small extracellular vesicles deliver miR-21 to promote corneal epithelial wound healing through PTEN\/PI3K\/Akt pathway","volume":"2022","author":"Liu","year":"2022","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.jconrel.2026.114729_bb0800","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.preteyeres.2015.11.002","article-title":"Pathogenesis and treatments of TGFBI corneal dystrophies","volume":"50","author":"Han","year":"2016","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2026.114729_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113700","article-title":"Hybrid micellar preparations for co-delivery of PARP-1 siRNA and quercetin for cataract treatment","volume":"382","author":"Zhang","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114729_bb0810","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202203257","article-title":"Nanoneedles induce targeted siRNA silencing of p16 in the human corneal endothelium","volume":"9","author":"Maurizi","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2026.114729_bb0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101524","article-title":"CRISPR-Cas9-mediated deletion of carbonic anhydrase 2 in the ciliary body to treat glaucoma","volume":"5","author":"Jiang","year":"2024","journal-title":"Cell Reports Med."},{"key":"10.1016\/j.jconrel.2026.114729_bb0820","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2025.102800","article-title":"A multistage microRNA nanotherapeutic to address fibrosis of bacterial keratitis","volume":"64","author":"Zhao","year":"2025","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2026.114729_bb0825","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1021\/acs.nanolett.9b02596","article-title":"Octopus-like flexible vector for noninvasive intraocular delivery of short interfering nucleic acids","volume":"19","author":"Jiang","year":"2019","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2026.114729_bb0830","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf409","article-title":"Modulation of TTR gene expression in the eye using modified siRNAs","volume":"53","author":"Hu","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2026.114729_bb0835","doi-asserted-by":"crossref","first-page":"11249","DOI":"10.1021\/acsnano.4c18924","article-title":"Direct cytosolic delivery of siRNA conjugates: a paradigm in antiangiogenic therapy for choroidal neovascularization","volume":"19","author":"Li","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114729_bb0840","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add4623","article-title":"Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates","volume":"9","author":"Herrera-Barrera","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.114729_bb0845","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.7150\/thno.99484","article-title":"Photoreceptor-targeted extracellular vesicles-mediated delivery of Cul7 siRNA for retinal degeneration therapy","volume":"14","author":"Guo","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2026.114729_bb0850","article-title":"Non-viral gene therapy using RNA interference with PDGFR-\u03b1 mediated epithelial-mesenchymal transformation for proliferative vitreoretinopathy","volume":"20","author":"Wang","year":"2023","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.jconrel.2026.114729_bb0855","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adl3576","article-title":"Suprachoroidal gene transfer with nonviral nanoparticles in large animal eyes","volume":"10","author":"Shen","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.114729_bb0860","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ymthe.2019.09.010","article-title":"Non-viral gene therapy for Stargardt disease with ECO\/pRHO-ABCA4 self-assembled nanoparticles","volume":"28","author":"Sun","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.114729_bb0865","doi-asserted-by":"crossref","first-page":"2500623","DOI":"10.1002\/adma.202500623","article-title":"High-efficiency ocular delivery of brain-derived neurotrophic factor and Oligomycin for neuroprotection in Glaucoma","volume":"37","author":"Cao","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.114729_bb0870","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jconrel.2019.05.010","article-title":"Gene delivery to the rat retina by non-viral vectors based on chloroquine-containing cationic niosomes","volume":"304","author":"Mashal","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114729_bb0875","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/10717544.2020.1731861","article-title":"Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy","volume":"27","author":"Li","year":"2020","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.114729_bb0880","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj0006","article-title":"Dynamically covalent lipid nanoparticles mediate CRISPR-Cas9 genome editing against choroidal neovascularization in mice","volume":"11","author":"Cao","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.114729_bb0885","doi-asserted-by":"crossref","first-page":"14756","DOI":"10.1021\/acsnano.4c16427","article-title":"A noninvasive Nanoeyedrop therapy for the inhibition of uveal melanoma: tetrahedral framework nucleic acid-based bioswitchable MicroRNA delivery system","volume":"19","author":"Jiang","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114729_bb0890","first-page":"231","article-title":"A review of recent developments in retinitis pigmentosa genetics, its clinical features, and natural course, medical hypothesis","author":"Loukovitis","year":"2021","journal-title":"Discov. Innov. Ophthalmol."},{"key":"10.1016\/j.jconrel.2026.114729_bb0895","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1016\/j.ymthe.2025.03.021","article-title":"Correcting a patient-specific Rhodopsin mutation with adenine base editor in a mouse model","volume":"33","author":"He","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.114729_bb0900","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1038\/s41467-021-25204-3","article-title":"Mirtron-mediated RNA knockdown\/replacement therapy for the treatment of dominant retinitis pigmentosa","volume":"12","author":"Orlans","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114729_bb0905","doi-asserted-by":"crossref","first-page":"14716","DOI":"10.1038\/ncomms14716","article-title":"Nrl knockdown by AAV-delivered CRISPR\/Cas9 prevents retinal degeneration in mice","volume":"8","author":"Yu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114729_bb0910","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax1210","article-title":"CRISPR-Cas9-mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis","volume":"5","author":"Jo","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.114729_bb0915","doi-asserted-by":"crossref","DOI":"10.1172\/JCI171356","article-title":"Nonviral base editing of KCNJ13 mutation preserves vision in a model of inherited retinal channelopathy","volume":"133","author":"Kabra","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2026.114729_bb0920","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41591-021-01297-7","article-title":"Durable vision improvement after a single treatment with antisense oligonucleotide sepofarsen: a case report","volume":"27","author":"Cideciyan","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.114729_bb0925","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0161-6420(91)32196-1","article-title":"Delayed rod dark adaptation in patients with Stargardt's disease","volume":"98","author":"Fishman","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2026.114729_bb0930","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1126\/science.277.5333.1805","article-title":"Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration","volume":"277","author":"Allikmets","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.114729_bb0935","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.3390\/ijms25042124","article-title":"Classical and innovative evidence for therapeutic strategies in retinal dysfunctions","volume":"25","author":"Caruso","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.114729_bb0940","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41418-020-00636-4","article-title":"Photoreceptor protection by mesenchymal stem cell transplantation identifies exosomal MiR-21 as a therapeutic for retinal degeneration","volume":"28","author":"Deng","year":"2021","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jconrel.2026.114729_bb0945","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jconrel.2024.04.036","article-title":"Small extracellular vesicles of organoid-derived human retinal stem cells remodel M\u00fcller cell fate via miRNA: a novel remedy for retinal degeneration","volume":"370","author":"Huang","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114729_bb0950","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1016\/j.ymthe.2024.09.027","article-title":"Safety and efficacy of CRISPR-mediated genome ablation of VEGFA as a treatment for choroidal neovascularization in nonhuman primate eyes","volume":"33","author":"Sin","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.114729_bb0955","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/s41467-018-04175-y","article-title":"CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of age-related macular degeneration","volume":"9","author":"Koo","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114729_bb0960","doi-asserted-by":"crossref","first-page":"7545","DOI":"10.1021\/jacs.4c16529","article-title":"DNA framework-enabled ocular barrier penetration for microinvasive antiangiogenic therapy","volume":"147","author":"Wang","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2026.114729_bb0965","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12951-024-03079-y","article-title":"Exosome-loading miR-205: a two-pronged approach to ocular neovascularization therapy","volume":"23","author":"Zhang","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2026.114729_bb0970","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adh0994","article-title":"An mRNA-encoded dominant-negative inhibitor of transcription factor RUNX1 suppresses vitreoretinal disease in experimental models","volume":"16","author":"O\u2019Hare","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.114729_bb0975","doi-asserted-by":"crossref","first-page":"21","DOI":"10.53388\/BMEC2025024","article-title":"MSAC U-net: multiscale AC block convolutional neural networks for blood vessel segmentation in fundus images","volume":"4","author":"Deng","year":"2025","journal-title":"Biomed. Eng. Commun."},{"key":"10.1016\/j.jconrel.2026.114729_bb0980","doi-asserted-by":"crossref","first-page":"14","DOI":"10.53388\/BMEC2025020","article-title":"AI-driven diabetic retinopathy detection for cancer patients: a novel attention AlexNet approach to mitigate psychological distress","volume":"4","author":"Ramamurthy","year":"2025","journal-title":"Biomed. Eng. Commun."},{"key":"10.1016\/j.jconrel.2026.114729_bb0985","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.phrs.2016.07.042","article-title":"Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat","volume":"111","author":"Amadio","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jconrel.2026.114729_bb0990","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.114729_bb0995","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","article-title":"Therapeutic siRNA: state-of-the-art and future perspectives","volume":"36","author":"Friedrich","year":"2022","journal-title":"Biodrugs"},{"key":"10.1016\/j.jconrel.2026.114729_bb1000","article-title":"A High-Fidelity RNA-targeting Cas13X downregulates Connexin43 in macroglia: a novel neuroprotective strategy for Glaucoma","volume":"12","author":"Zhao","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2026.114729_bb1005","article-title":"Circulating small extracellular vesicles involved in systemic regulation respond to RGC degeneration in Glaucoma","volume":"11","author":"Li","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2026.114729_bb1010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.13004\/kjnt.2018.14.1.1","article-title":"Traumatic optic neuropathy","volume":"14","author":"Jang","year":"2018","journal-title":"Korean J. Neurotrauma"},{"key":"10.1016\/j.jconrel.2026.114729_bb1015","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40265-019-01129-6","article-title":"Tafamidis: a review in transthyretin amyloidosis with polyneuropathy","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2026.114729_bb1020","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2026.114729_bb1025","article-title":"Allele-specific depletion of Q209L via siRNA or an rAAV2-shRNA vector induces selective toxicity in Q209L uveal melanoma cells","volume":"33","author":"McCall","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.jconrel.2026.114729_bb1030","doi-asserted-by":"crossref","DOI":"10.1172\/JCI171356","article-title":"Nonviral base editing of mutation preserves vision in a model of inherited retinal channelopathy","volume":"133","author":"Kabra","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2026.114729_bb1035","doi-asserted-by":"crossref","first-page":"1902776","DOI":"10.1002\/smll.201902776","article-title":"Anti-VEGF-aptamer modified C-dots-A hybrid nanocomposite for topical treatment of ocular vascular disorders","volume":"15","author":"Shoval","year":"2019","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2026.114729_bb1040","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102258","article-title":"Circular RNA-based therapy provides sustained and robust neuroprotection for retinal ganglion cells","volume":"35","author":"Jiang","year":"2024","journal-title":"Mol. Ther. Nucl. Acids"},{"key":"10.1016\/j.jconrel.2026.114729_bb1045","doi-asserted-by":"crossref","first-page":"2417363","DOI":"10.1002\/advs.202417363","article-title":"Magnetic-guided delivery of antisense oligonucleotides for targeted transduction in multiple retinal explant and organoid models","volume":"12","author":"Ye","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2026.114729_bb1050","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/smll.201303201","article-title":"Layer-by-layer nanoparticles as an efficient siRNA delivery vehicle for SPARC silencing","volume":"10","author":"Tan","year":"2014","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2026.114729_bb1055","doi-asserted-by":"crossref","first-page":"2400815","DOI":"10.1002\/smll.202400815","article-title":"Preformed vesicle approach to LNP manufacturing enhances retinal mRNA delivery","volume":"20","author":"Eygeris","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2026.114729_bb1060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114027","article-title":"Efficacy versus immunogenicity of LNP-mediated delivery of mRNA and self-amplifying RNA upon intravitreal injection in the mouse eye","volume":"385","author":"Li","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114729_bb1065","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1038\/s41467-023-42189-3","article-title":"Lipid nanoparticles with PEG-variant surface modifications mediate genome editing in the mouse retina","volume":"14","author":"Gautam","year":"2023","journal-title":"Nat. Commun."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926001318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926001318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T08:40:33Z","timestamp":1787128833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926001318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":213,"alternative-id":["S0168365926001318"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114729","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nucleic acid drug delivery in ophthalmology: Emerging trends and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114729","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114729"}}